Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB Dose-Escalation Study of Pemetrexed and AUY922 in Previously-Treated Patients With Metastatic Non-Squamous, Non-Small Cell Lung Cancer

Trial Profile

A Phase IB Dose-Escalation Study of Pemetrexed and AUY922 in Previously-Treated Patients With Metastatic Non-Squamous, Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2019

At a glance

  • Drugs Luminespib (Primary) ; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Apr 2019 Status changed from active, no longer recruiting to completed.
    • 26 Sep 2018 Results (n=13) presented at the 19th World Conference on Lung Cancer
    • 23 Aug 2013 Planned End Date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top